Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: Rare but possible

22Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We describe a case of virological failure during initial treatment with tenofovir disoproxil fumarate/emtricitabine/dolutegravir twice daily, with concomitant rifampin treatment of staphylococcal infection, selection of R263K + E157Q, and low plasma dolutegravir levels. Using rifampin together with dolutegravir may require closer follow-up, and, if possible, plasma dolutegravir levels should be monitored.

Author supplied keywords

References Powered by Scopus

Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection

742Citations
N/AReaders
Get full text

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study

468Citations
N/AReaders
Get full text

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

446Citations
N/AReaders
Get full text

Cited by Powered by Scopus

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

49Citations
N/AReaders
Get full text

Emergent resistance to dolutegravir among instinaive patients on first-line or second-line antiretroviral therapy: A review of published cases

34Citations
N/AReaders
Get full text

Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient

20Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Pena, M. J., Chueca, N., D’Avolio, A., Zarzalejos, J. M., & Garcia, F. (2019, January 1). Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: Rare but possible. Open Forum Infectious Diseases. Oxford University Press. https://doi.org/10.1093/ofid/ofy332

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 26

76%

Professor / Associate Prof. 4

12%

Researcher 3

9%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

50%

Pharmacology, Toxicology and Pharmaceut... 6

19%

Biochemistry, Genetics and Molecular Bi... 6

19%

Nursing and Health Professions 4

13%

Article Metrics

Tooltip
Mentions
Blog Mentions: 2
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free